Lv3
256 积分 2025-04-28 加入
LPA 1 ‐induced cytoskeleton reorganization drives fibrosis through CTGF‐dependent fibroblast proliferation
1个月前
已完结
Blockade of lysophosphatidic acid receptors LPAR1/3 ameliorates lung fibrosis induced by irradiation
1个月前
已完结
Pamrevlumab for Idiopathic Pulmonary Fibrosis
1个月前
已完结
Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis
1个月前
已完结
Ziritaxestat, a Novel Autotaxin Inhibitor, and Lung Function in Idiopathic Pulmonary Fibrosis
2个月前
已完结
The novel lysophosphatidic acid receptor 1-selective antagonist, ACT-1016-0707, has unique binding properties that translate into effective antifibrotic and anti-inflammatory activity in different models of pulmonary fibrosis
2个月前
已完结
Discovery of a Novel Orally Active, Selective LPA Receptor Type 1 Antagonist, 4-(4-(2-Isopropylphenyl)-4-((2-methoxy-4-methylphenyl)carbamoyl)piperidin-1-yl)-4-oxobutanoic Acid, with a Distinct Molecular Scaffold
2个月前
已完结
Discovery of the Novel, Orally Active, and Selective LPA1 Receptor Antagonist ACT-1016-0707 as a Preclinical Candidate for the Treatment of Fibrotic Diseases
2个月前
已完结
The novel lysophosphatidic acid receptor 1-selective antagonist, ACT-1016-0707, has unique binding properties that translate into effective antifibrotic and anti-inflammatory activity in different models of pulmonary fibrosis
2个月前
已完结
Structure Based Discovery and Anti-fibrotic Activity of Novel Antagonists of Lysophosphatidic Acid Receptor 1 (LPAR1)
2个月前
已关闭
皖公网安备34019202002308
